Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pinching-off of Coated Vesicles01:32

Pinching-off of Coated Vesicles

Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural insights into the role and targeting of EGFRvIII.

Structure (London, England : 1993)·2024
Same author

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias.

Nature·2022
Same author

Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.

Protein science : a publication of the Protein Society·2020
Same author

Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain.

Structure (London, England : 1993)·2018
Same author

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.

Molecular cancer therapeutics·2017
Same author

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Cell·2017
Same journal

Structure of Perinereis linea erythrocruorin reveals a compact extracellular globin megacomplex.

Structure (London, England : 1993)·2026
Same journal

Meet the author: Stephen Brohawn.

Structure (London, England : 1993)·2026
Same journal

Tetraspanins bring Norrin into focus: Structural insights into ligand-specific Wnt signaling.

Structure (London, England : 1993)·2026
Same journal

Uncovering subtype-selective activation of the K<sub>Ca</sub>3.1 channel by SKA-111.

Structure (London, England : 1993)·2026
Same journal

Identification and structure determination of a type III-Bv CRISPR complex that post-translationally modifies an associated toxin.

Structure (London, England : 1993)·2026
Same journal

Cryo-EM structure of the Arabidopsisthaliana ribosome in translating and non-translating states.

Structure (London, England : 1993)·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

A Method For Production of Recombinant mCD1d Protein in Insect Cells.
09:41

A Method For Production of Recombinant mCD1d Protein in Insect Cells.

Published on: December 10, 2007

Discoidin discoveries.

Kathryn M Ferguson1

  • 1Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. ferguso2@mail.med.upenn.edu

Structure (London, England : 1993)
|April 10, 2012
PubMed
Summary
This summary is machine-generated.

Researchers explored how antibodies block discoidin domain receptor 1 (DDR1) signaling. This research offers new understanding into the activation mechanisms of DDRs, which have distinct extracellular regions among receptor tyrosine kinases.

More Related Videos

High-throughput Measurement of Dictyostelium discoideum Macropinocytosis by Flow Cytometry
06:47

High-throughput Measurement of Dictyostelium discoideum Macropinocytosis by Flow Cytometry

Published on: September 10, 2018

Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on Bacteria
06:08

Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on Bacteria

Published on: January 25, 2019

Related Experiment Videos

Last Updated: May 23, 2026

A Method For Production of Recombinant mCD1d Protein in Insect Cells.
09:41

A Method For Production of Recombinant mCD1d Protein in Insect Cells.

Published on: December 10, 2007

High-throughput Measurement of Dictyostelium discoideum Macropinocytosis by Flow Cytometry
06:47

High-throughput Measurement of Dictyostelium discoideum Macropinocytosis by Flow Cytometry

Published on: September 10, 2018

Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on Bacteria
06:08

Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on Bacteria

Published on: January 25, 2019

Area of Science:

  • Biochemistry
  • Structural Biology
  • Cell Signaling

Background:

  • Discoidin domain receptors (DDRs) are receptor tyrosine kinases with unique extracellular regions.
  • Understanding DDR activation is crucial for targeted therapies.
  • Antibody-mediated inhibition offers a potential therapeutic strategy.

Discussion:

  • Carafoli et al. elucidate the mechanism of antibody-mediated inhibition of discoidin domain receptor 1 (DDR1).
  • The study provides structural insights into how antibodies interact with DDR1.
  • This work contributes to the understanding of DDR signaling pathways.

Key Insights:

  • Antibodies can effectively inhibit DDR1 activity through specific binding modes.
  • The extracellular region's composition influences DDR activation and inhibitor binding.
  • New structural information clarifies the antibody-DDR1 interaction interface.

Outlook:

  • Further investigation into DDR activation mechanisms can reveal new therapeutic targets.
  • Developing specific DDR inhibitors holds promise for treating diseases involving aberrant signaling.
  • Structural studies are key to designing potent and selective antibody-based therapeutics for DDRs.